COVID-19 Infection in Diabetic Patients

NCT ID: NCT04765254

Last Updated: 2021-02-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-20

Study Completion Date

2021-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It was observed during the last period of COVID-19 pandemic that diabetic patients had a worse prognosis and more deteriorated clinical features than other patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetic patients infected with SAR-COV-19 were reported to have worse prognosis and faster deterioration in addition to higher rate for ICU admission when compared to other infected patients. In this study authors aim to investigate the certain cause for their case deterioration to be modified for better prognosis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Diabete Type 2 Non Diabetic Patients Chest CT Scan

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

COVID-19 infected patients with no other comorbidities and they take the routine protocol from the Egyptian ministry of health

no intervention as it is an observational study

Intervention Type OTHER

both groups will be monitored for the disease progress or deterioration and mortality rate

diabetic group

COVID-19 infected patients with diabetes comorbidity and they receive the routine protocol for covid treatment in addition to their hypoglycemic drugs

no intervention as it is an observational study

Intervention Type OTHER

both groups will be monitored for the disease progress or deterioration and mortality rate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention as it is an observational study

both groups will be monitored for the disease progress or deterioration and mortality rate

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients infected with COVID-19 male or female 30 years old or more inpatients

Exclusion Criteria

* have othe comorbidities other than type 2 diabetes mellitus pregnant women below 30 years old
Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dalia K. Zaafar

lecturer of pharmacology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairo University teaching hospitals

Cairo, Kasr Al Ainy, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dalia Zaafar, PhD

Role: CONTACT

+201117922833

Amal Ahmed, PhD

Role: CONTACT

+201224847367

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amal Ahmed, PhD

Role: primary

+201224847367

Dalia Zaafar, PhD

Role: backup

+201117922833

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ITH00131

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.